摘要:
Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
摘要:
The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or higher level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
摘要:
The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.
摘要翻译:本公开涉及特异性结合具有SEQ ID No.29的氨基酸序列的肽(CK-8的片段)的人CK8抗原肽,抗体或其抗体片段或人源化抗体。 所述分子可用于在其表面上检测和/或治疗其细胞表达CK8蛋白的肿瘤,特别是根据SEQ ID No.29的序列的肽。
摘要:
The present invention relates to the production of recombinant glycoproteins or antibodies that have an improved glycosylation profile and effector functions such as ADCC and/or CDC. The present invention is in particular related to the production of glycoproteins or antibodies having a valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and /or presence of sialic acid to the glycans.
摘要:
The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or higher level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
摘要:
The present disclosure relates to binding specifically to the DR5 receptor and that comprise specific CDRs and variations at positions 326, 333 and 396 (Fc region) which may provide to regulate apoptosis potency. The variants have no modified glycan profiles. The present disclosure claims pharmaceutical compositions and the treatment of cancers, autoimmune disease, inflammatory disease or condition, infectious disease, e.g. viral infection and viral disease, neurological disorder.
摘要:
The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or presence of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.